Chimiothérapie des tumeurs germinales de stade I : pour qui ? Comment ?

  • S. Culine
Part of the Monographies en urologie book series (MONOGRAPHIES)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Droz JP, van Oosterom AT (1993) Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: a wager on the future ? A review. Eur J Cancer 29A: 1038–44PubMedGoogle Scholar
  2. 2.
    Vergouwe Y, Steyerberg EW, Eijkemans MJC et al. (2003) Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21: 4092–9PubMedCrossRefGoogle Scholar
  3. 3.
    Madej G, Pawinski A (1991) Risk-related adjuvant chemotherapy for stage I non seminoma of the testis. Clin Oncol 3: 270–2CrossRefGoogle Scholar
  4. 4.
    Oliver RTD, Raja MA, Ong J et al. (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I cancer patients. J Urol 148: 1453–6PubMedGoogle Scholar
  5. 5.
    Cullen MH, Stenning SP, Parkinson MC et al. (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 14: 1106–13PubMedGoogle Scholar
  6. 6.
    Pont J, Albrecht W, Postner G et al. (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14: 441–8PubMedGoogle Scholar
  7. 7.
    Chevreau C, Soulié M, Rischmann P et al. (1997) Adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumors. Proc Am Soc Clin Oncol 16: 320 a (abstr.)Google Scholar
  8. 8.
    Klepp O, Dahl O, Flodgren P et al. (1997) Risk-adapted treatment of clinical stage I nonseminoma testis cancer. Eur J Cancer 33: 1038–44PubMedCrossRefGoogle Scholar
  9. 9.
    Dearnaley DP, Fossa SD, Kaye SB et al. (1998) Adjuvant bleomycin, vincristine and cisplatin for high risk clinical stage I non-seminomatous germ cell tumours. A Medical Research Council pilot study. Proc Am Soc Clin Oncol 17: 309a (abstr.)Google Scholar
  10. 10.
    Ondrus D, Matoska J, Belan V et al. (1998) Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 33: 562–6PubMedGoogle Scholar
  11. 11.
    Böhlen D, Borner M, Sonntag RW et al. (1999) Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161: 1148–52PubMedGoogle Scholar
  12. 12.
    Moul JW, McCarthy WF, Fernandez EB et al. (1994) Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 54: 362–4PubMedGoogle Scholar
  13. 13.
    Böhlen D, Burckhard FC, Mills R et al. (2001) Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 165: 441–4PubMedGoogle Scholar
  14. 14.
    Warde P, Specht L, Horwich A et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20: 4448–52PubMedCrossRefGoogle Scholar
  15. 15.
    Gospodarowicz MK, Sturgeon JFG, Jewett MAS (1998) Early stage and advanced seminoma: role of radiation therapy, surgery and chemotherapy. Semin Oncol 25: 160–73Google Scholar
  16. 16.
    Sharda NN, Kinsella TJ, Ritter MA (1996) Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 14: 2933–9PubMedGoogle Scholar
  17. 17.
    Oliver RTD, Edmonds PM, Ong JYH et al. (1994) Pilot studies of two and one course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy ? Int J Radiat Oncol Biol Phys 29: 3–8PubMedGoogle Scholar
  18. 18.
    Reiter WJ, Brodowicz T, Alavi S et al. (2001) Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 19: 101–4PubMedGoogle Scholar
  19. 19.
    Aparicio J, Garcia del Muro X, Maroto P et al. (2003) Multicenter study evaluating a dual policy of postorchidectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann Oncol 14: 867–72PubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2006

Authors and Affiliations

  • S. Culine
    • 1
  1. 1.Service d’oncologie médicale du Pr CulineCentre Val d’AurelleMontpellier Cedex 5

Personalised recommendations